New trends associated with disease activity in patients with ulcerative colitis

New trends in ulcerative colitis



Ulcerative colitis, neutrophil-lymphocyte ratio, platelet-lymphocyte ratio, C-reactive protein, erythrocyte sedimentation rate


Background/Aim: The severity and extent of ulcerative colitis (UC) guide us in determining the treatment method for each case. It has been suggested in the literature that high neutrophil-lymphocyte and platelet-lymphocyte ratios can serve as markers of active ulcerative colitis. This study retrospectively analyzes the relationship between neutrophil-lymphocyte ratio and platelet-lymphocyte ratio with clinical activity indices and endoscopic activity indices in predicting disease severity in patients with ulcerative colitis. There are few studies in the literature regarding the relationship between platelet-lymphocyte ratio (PLR) and disease activation in ulcerative colitis. This study contributes to the follow-up and outcomes of these patients, as there is a lack of sufficient retrospective studies on the platelet/lymphocyte ratio in patients diagnosed with UC in our country and worldwide.

Methods: This study is a population-based, single-center, case-controlled study. It was conducted by retrospectively analyzing the hospital information system for data recorded during the routine diagnosis and treatment of ulcerative colitis patients followed and treated at Celal Bayar University Medical Faculty Gastroenterology Division between January 2014 and December 2021. A total of 135 patients with ulcerative colitis were included in the study. The patients were divided into 2 groups, active disease and disease in remission, based on clinical activity indices and endoscopic activity indices. Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin (Hb), white blood cell (WBC), neutrophil-lymphocyte ratio (NLR), and platelet-lymphocyte ratio (PLR) levels were checked during routine follow-up of patients with ulcerative colitis. These values were recorded at the first presentation to the hospital and 3 months after treatment.

Results: Laboratory values at presentation were compared with those at the third month of treatment in a group of 113 patients with UC in remission: NLR (5.529 (3.485) and 4.374 (2.335), [P<0.001]), erythrocyte sedimentation rate (26.81 (20.42) and 21.78 (19.32), [P=0.015]), C-reactive protein (4.087 (6.729) and 1.696 (3.525), [P<0.001]), and white blood cell count (9,864 (3,514) and 8,067 (1,927), [P<0.001]) were found to be lower than the baseline values. As expected, decreases in inflammatory markers were observed in patients in remission. In a group of 22 patients with active disease, values at presentation were compared with those at the third month of treatment: neutrophil count (8,508 (2,908) and 9,646 (3,265), [P=0.037]) and platelet count (289,591 (95,123) and 323,364 (127,647), [P=0.010]) were found to be high. Similarly, ESR (19.63 (15.43) and 27.89 (21.11), [P=0.036]) was found to be high. These values were higher in active disease compared to the time of admission.

Conclusion: In our study, neutrophil-lymphocyte ratios and platelet-lymphocyte ratios were significantly higher in patients with active ulcerative colitis. The level of inflammatory markers in ulcerative colitis patients at the time of diagnosis and in the early stages of the disease is helpful in predicting the course of the disease, and this was shown to be related to clinical, endoscopic, and laboratory indices. These inflammatory markers can predict disease activity alone or in combination. However, a threshold value could not be calculated due to the insufficient number of patients, and thus, more comprehensive prospective studies are needed.


Download data is not yet available.


Osterman MT, Lichtenstein GR. Ulcerative Colitis. In: Feldman M, Friedman LS, Brandt LJ, editors. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. 2. 10 ed. Philadelphia: Elsevier, Saunders; 2016.2023-6.

Azad S, Sood N, Sood A. Biological and histological parameters as predictors of relapse in ulcerative colitis: a prospective study. Saudi J Gastroenterol. 2011 May-Jun;17(3):194-8. doi: 10.4103/1319-3767.80383. PMID: 21546723; PMCID: PMC3122090. DOI:

Solem CA, Loftus EV, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis. 2005;11(8):707-12. DOI:

Posul E, Yilmaz B, Aktas G, Kurt M. Does neutrophil-to-lymphocyte ratio predict active ulcerative colitis? Wiener klinische Wochenschrift. 2015;127(7-8):262-5. DOI:

Bhat T, Teli S, Rijal J, Bhat H, Raza M, Khoueiry G, et al. Neutrophil to lymphocyte ratio and cardiovascular diseases: a review. Expert Rev Cardiovasc Ther. 2013 Jan;11(1):55-9. doi: 10.1586/erc.12.159. PMID: 23259445. DOI:

Gary T, Pichler M, Belaj K, Hafner F, Gerger A, Froehlichet H, et al. Platelet-to-lymphocyte ratio: a novel marker for critical limb ischemia in peripheral arterial occlusive disease patients. PLoS One. 2013 Jul 2;8(7):e67688. doi: 10.1371/journal.pone.0067688. PMID: 23844064; PMCID: PMC3699634. DOI:

Jilma B, Blann A, Pernerstorfer T, Stohlawetz P, Eichler HG, Vondrovec B, et al. Regulation of adhesion molecules during human endotoxemia. No acute effects of aspirin. Am J Respir Crit Care Med. 1999;159(3):857–63. DOI:

O’Mahony JB, Palder SB, Wood JJ, McIrvine A , Rodrick ML, Demling RH, et al. Depression of cellular immunity after multiple trauma in the absence of sepsis. J Trauma. 1984 Oct;24(10):869-75. doi: 10.1097/00005373-198410000-00001. PMID: 6238173. DOI:

Alexandrakis MG, Passam FH, Moschandrea IA, Christophoridou AV, Pappa CA, Coulocheri SA, et al. Levels of serum cytokines and acute phase proteins in patients with essential and cancer-related thrombocytosis. Am J Clin Oncol. 2003;26(2):135–40. DOI:

Yaşa H. Turkiye Klinikleri J Gastroenterohepatology-Special Topics. 2012;5(3):71-83.

Truelove SC, Witts LJ. Cortisone in ulcerative colitis; final report on a therapeutic trial. Br Med J. 1955 Oct 29;2(4947):1041-8. doi: 10.1136/bmj.2.4947.1041. PMID: 13260656; PMCID: PMC1981500. DOI:

Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. The New England Journal of Medicine. 1987;317(26):1625-9. DOI:

Torun S, Tunc BD, Suvak B, Yildiz H, Taset A, Sayılır A, et al. Assessment of neutrophil lymphocyte ratio in ulcerative colitis: A promising marker in predicting disease severity. Clin Res Hepatol Gastroenterol. 2012;36(5):491–7. DOI:

Yamamoto-Furusho JK, Mendieta-Escalante EA. Diagnostic utility of the neutrophil-platelet ratio as a novel marker of activity in patients with Ulcerative Colitis. PLoS One. 2020 Apr 21;15(4):e0231988. doi: 10.1371/journal.pone.0231988. PMID: 32315368; PMCID: PMC7173773. DOI:

Celikbilek M, Dogan S, Ozbakir O, Zararsiz G, Kücük H, Gürsoy S, et al. Neutrophil-Lymphocyte Ratio as a Predictor of Disease Severity in Ulcerative Colitis. J Clin Lab Anal. 2013;27(1):72–6. DOI:

Nishida Y, Hosomi S, Yamagami H, Yukawa T, Otani K, Nagami Y, et al. Neutrophil-to-Lymphocyte Ratio for Predicting Loss of Response to Infliximab in Ulcerative Colitis. PLoS One. 2017 Jan 11;12(1):e0169845. doi: 10.1371/journal.pone.0169845. PMID: 28076386; PMCID: PMC5226844. DOI:

Akpinar MY, Ozin YO, Kaplan M, Ates I, Kalkan IH, Kilic ZMY, et al. Platelet-to-lymphocyte Ratio and Neutrophil-to-lymphocyte Ratio Predict Mucosal Disease Severity in Ulcerative Colitis. J Med Biochem. 2018 Apr 1;37(2):155-62. doi: 10.1515/jomb-2017-0050. PMID: 30581352; PMCID: PMC6294094. DOI:

Demir AK, Demirtaş A, Kaya SU, Tastan I, Butun I, Sagcan M, et al. The relationship between the neutrophil-lymphocyte ratio and disease activity in patients with ulcerative colitis. Kaohsiung J Med Sci. 2015 Nov;31(11):585-90. doi: 10.1016/j.kjms.2015.10.001. Epub 2015 Oct 31. PMID: 26678939. DOI:

Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009;197(4):466–72. DOI:

Kwon HC, Kim SH, Oh SY, Lee S, Lee JH, Choi HJ, et al. Clinical significance of preoperative neutrophil-lymphocyte versus platelet-lymphocyte ratio in patients with operable colorectal cancer. Biomarkers. 2012;17(3):216–22. DOI:

Bengi G, Keyvan H, Durmaz SB, Akpınar H. Frequency, types, and treatment of anemia in Turkish patients with inflammatory bowel disease. World J Gastroenterol. 2018 Sep 28;24(36):4186-96. doi: 10.3748/wjg.v24.i36.4186. PMID: 30271083; PMCID: PMC6158484. DOI:

Ha JS, Lee JS, Kim HJ, Moon TG, Chang DK, Lee JH, et al. [Comparative usefulness of erythrocyte sedimentation rate and C-reactive protein in assessing the severity of ulcerative colitis]. Korean J Gastroenterol. 2006 Nov;48(5):313-20. Korean. PMID: 17132919.

Uzun ES, Şimşek EE, Tüzün S, Orbay E, Emel Ahishali E, Mustafa Reşat Dabak MR. İnflamatuar Barsak Hastalıklarının Aktivasyonunda İnflamasyon ile Hemogram Parametrelerinin İlişkisi. Kafkas Journal of Medical Sciences. 2018 Ağustos;8(2):83-7. doi: 10.5505/kjms.2018.32650. DOI:

Kopylov U, Rosenfeld G, Bressler B, Seidman E. Clinical utility of fecal biomarkers for the diagnosis and management of inflammatory bowel disease. Inflamm Bowel Dis. 2014 Apr;20(4):742-56. doi: 10.1097/01.MIB.0000442681.85545.31. PMID: 24562174. DOI:

Yoon JY, Park SJ, Hong SP, Kim TI, Kim WH, Cheon JH. Correlations of C-reactive protein levels and erythrocyte sedimentation rates with endoscopic activity indices in patients with ulcerative colitis. Dig Dis Sci. 2014 Apr;59(4):829-37. doi: 10.1007/s10620-013-2907-3. Epub 2013 Dec 19. PMID: 24352705. DOI:

Ibarra-Rodriguez JJ, Santiago-Luna E, Velazquez-Ramirez GA, Lopez-Ramirez MK, Fuentes-Orozco C, Cortes-Flores AO, et al. [Sensitivity, specificity, and predictive values of the level of hemoglobin, hematocrit and platelet count as an activity index in ulcerative colitis]. Cirugia Ycirujanos. 2005;73(5):355-62.






Research Article

How to Cite

Buran T, Kılınç SGM, Sahin M. New trends associated with disease activity in patients with ulcerative colitis: New trends in ulcerative colitis. J Surg Med [Internet]. 2024 Feb. 15 [cited 2024 Apr. 23];8(2):36-41. Available from: